Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.28
+0.38 (4.81%)
At close: Mar 4, 2026, 4:00 PM EST
8.28
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:10 PM EST

Gyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
7531,0441,9681729139
Market Cap Growth
-26.80%-46.93%11690.14%-41.61%-79.50%70.05%
Enterprise Value
693.691,0542,02921.82-15.8861.73
Last Close Price
8.2812.1025.697.9513.6594.65
PE Ratio
211.54242.00-18.22265.0056.88-2.15
Forward PE
38.51-----
PS Ratio
7.029.8717.340.163.903.33
PB Ratio
7.3816.49-124.320.390.701.83
P/TBV Ratio
8.0119.55-106.8514.1522.161.59
P/FCF Ratio
259.87-175.34113.252.93-0.34-2.52
P/OCF Ratio
194.11-286.8276.001.56-0.34-2.53
EV/Sales Ratio
6.479.9717.880.21-2.161.47
EV/EBITDA Ratio
48.3159.53-30.672.120.18-1.08
EV/EBIT Ratio
57.6465.23-30.182.370.18-1.08
EV/FCF Ratio
239.53-177.02116.773.830.19-1.12
Debt / Equity Ratio
0.010.020.030.010.060.02
Debt / EBITDA Ratio
0.090.09-0.010.06-0.03-0.03
Debt / FCF Ratio
0.40-0.270.020.11-0.03-0.03
Net Debt / Equity Ratio
-0.58-0.402.09-0.58-1.08-1.02
Net Debt / EBITDA Ratio
-4.49-1.420.50-2.390.511.36
Net Debt / FCF Ratio
-20.334.21-1.90-4.320.531.41
Asset Turnover
0.750.871.131.460.100.43
Inventory Turnover
0.640.730.891.57--
Quick Ratio
5.462.862.513.463.444.65
Current Ratio
6.193.322.854.063.635.03
Return on Equity (ROE)
10.02%31.86%-198.41%7.61%-150.11%-77.89%
Return on Assets (ROA)
6.54%10.30%-74.19%6.01%-116.80%-59.33%
Return on Invested Capital (ROIC)
10.64%15.70%-123.49%17.93%6266.95%-1331.86%
Return on Capital Employed (ROCE)
9.65%15.97%-79.56%16.14%-148.29%-78.21%
Earnings Yield
0.88%0.41%-5.49%0.38%1.76%-46.43%
FCF Yield
0.38%-0.57%0.88%34.10%-295.96%-39.67%
Buyback Yield / Dilution
-2.27%-0.25%0.00%0.00%-173.37%-43.30%
Updated Nov 7, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q